DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cobimetinib
Drug: Atezolizumab
Drug: Venetoclax

First Posted Date: 2017-10-17

Last Posted Date: 2023-02-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT03312530

Locations: 🇫🇷
CHU - Hôtel Dieu hematolgie clinique, Nantes, France
🇨🇿
Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava, Czechia
🇨🇿
Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia

and more 23 locations

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 4

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab
Drug: NSAIDs
Drug: CSs
Drug: MTX

First Posted Date: 2017-10-04

Last Posted Date: 2024-01-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 62

Registration Number: NCT03301883

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳
Shanghai Children's Medical Center; Renal rheumatology, Shanghai City, China
🇨🇳
Capital Institute of Pediatrics, Beijing City, China

and more 7 locations

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Glaucoma, Open-angle
Ocular Hypertension

Interventions: Drug: 0.01% RO7058584
Drug: 1% RO7058584
Drug: Matching Placebo
Drug: 0.1% RO7058584
Drug: Latanoprost 0.005%

First Posted Date: 2017-09-26

Last Posted Date: 2020-03-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 27

Registration Number: NCT03293992

Locations: 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸
Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow, Georgia, United States
🇺🇸
Rocky Mountain Lions Eye Inst, Aurora, Colorado, United States

and more 5 locations

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer
Advanced Ovarian Cancer

Interventions: Drug: Atezolizumab
Drug: RO6870810

First Posted Date: 2017-09-25

Last Posted Date: 2020-11-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT03292172

Locations: 🇨🇦
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇺🇸
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States
🇬🇧
The Christie, Manchester, United Kingdom

and more 8 locations

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Glucocorticoid Agent

First Posted Date: 2017-09-25

Last Posted Date: 2020-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 101

Registration Number: NCT03291457

Locations: 🇧🇪
Private Practice Els Van Essche, Bonheiden, Belgium
🇧🇪
Rhumarc sciv sprl, Céroux-Mousty, Belgium
🇧🇪
CHC MontLégia, Liege, Belgium

and more 19 locations

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: MabThera

First Posted Date: 2017-09-20

Last Posted Date: 2021-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 701

Registration Number: NCT03289182

Locations: 🇰🇷
Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of

and more 22 locations

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Phase 2

Terminated

Conditions: Polycythemia Vera

Interventions: Drug: Idasanutlin

First Posted Date: 2017-09-19

Last Posted Date: 2021-12-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 27

Registration Number: NCT03287245

Locations: 🇺🇸
University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States

and more 8 locations

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 4

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab

First Posted Date: 2017-09-18

Last Posted Date: 2025-01-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 619

Registration Number: NCT03285763

Locations: 🇦🇷
Hospital Aleman, Caba, Argentina
🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇧🇷
CETUS Hospital Dia Oncologia, Uberaba, MG, Brazil

and more 108 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1

Active, not recruiting

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: BL-8040
Biological: PEGylated recombinant human hyaluronidase (PEGPH20)
Biological: Ramucirumab
Drug: Linagliptin
Drug: Leucovorin
Drug: Cobimetinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Tiragolumab
Drug: Atezolizumab

First Posted Date: 2017-09-13

Last Posted Date: 2025-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 410

Registration Number: NCT03281369

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇮🇱
Rambam Health Care Campus, Haifa, Israel

and more 20 locations

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Completed

Conditions: Nasal Polyps
Chronic Rhinosinusitis

Interventions: Drug: Placebo
Drug: Omalizumab

First Posted Date: 2017-09-12

Last Posted Date: 2020-03-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280550

Locations: 🇺🇸
Northwell Health, Great Neck, New York, United States
🇨🇦
CHAUQ Hospital St Sacrement, Quebec, Canada
🇨🇦
Ottawa Allergy Research Corp, Ottawa, Ontario, Canada

and more 34 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy